User reported effectiveness ratings Mobic/Movalis/Melox/Recoxa (Meloxicam) for various conditions.
|Conditions||Major Improvement||Moderate Improvement||Much Worse||No Effect||Worse||Responses|
|Ehlers-Danlos Syndrome, Hypermobility||24%||35%||6%||35%||0%||17|
Below is the degree of change seen after Mobic/Movalis/Melox/Recoxa (Meloxicam) is higher than average.
Don't see what you're looking for?
Create a study and help us eradicate suffering!
Below is the change in the listed outcome after is higher than average.
(Math.abs(a['change']) < Math.abs(b['change'])) ? 1 : -1)" title="Click to put the results with the largest observed change at the top"> Sort by Effect Size
(a['number_of_days'] < b['number_of_days']) ? 1 : -1)" title="Click to put the results with the most supporting data points at the top."> Sort by Confidence
Mobic/Movalis/Melox/Recoxa (Meloxicam) Info
|Variable Name||Mobic/Movalis/Melox/Recoxa (Meloxicam)|
|Analysis Performed At||2020-05-05|
|Duration of Action||21 days|
|Minimum Allowed Value||0 count|
|Number of Aggregate Predictors||0|
|Number of Aggregate Outcomes||0|
|Number of Measurements||0|
|Number of Measurements (including those generated by tagged, joined, or child variables)||0|
|Onset Delay||30 minutes|